Similar articles for PMID: 19535920

Year	Number of Results
1983	1
1986	1
1987	2
1989	1
1990	2
1991	1
1992	2
1994	1
1995	1
1996	1
1997	1
2000	1
2001	3
2002	1
2003	2
2004	5
2005	5
2006	8
2007	12
2008	4
2009	9
2010	11
2011	10
2012	13
2013	8
2014	7
2015	6
2016	8
2017	9
2018	6
2019	10
2020	14
2021	13
2022	6
2023	4
2024	0

1

Immune memory to hepatitis B virus in 4-9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine.

Zinke M, Kappes R, Kindler K, Paulus-Koschik A, Goering U, Disselhoff J, Soemantri P, Grunert D, Laakmann KH, Gunasekaran R, Gartner B, Jacquet JM. Zinke M, et al. Hum Vaccin. 2009 Sep;5(9):592-8. doi: 10.4161/hv.9051. Epub 2009 Sep 20. Hum Vaccin. 2009. PMID: 19535920

2

Lasting immune memory against hepatitis B following challenge 10-11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11-12 months of age.

Avdicova M, Crasta PD, Hardt K, Kovac M. Avdicova M, et al. Vaccine. 2015 May 28;33(23):2727-33. doi: 10.1016/j.vaccine.2014.06.070. Epub 2014 Jun 22. Vaccine. 2015. PMID: 24962750

3

Lasting immune memory against hepatitis B in 12-13-year-old adolescents previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy.

Behre U, Van Der Meeren O, Crasta P, Hanssens L, Mesaros N. Behre U, et al. Hum Vaccin Immunother. 2016 Nov;12(11):2916-2920. doi: 10.1080/21645515.2016.1202388. Epub 2016 Sep 21. Hum Vaccin Immunother. 2016. PMID: 27653771 Free PMC article. Clinical Trial.

4

Long-term antibody persistence against hepatitis B in adolescents 14-15-years of age vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy.

Schwarz TF, Behre U, Adelt T, Donner M, Suryakiran PV, Janssens W, Mesaros N, Panzer F. Schwarz TF, et al. Hum Vaccin Immunother. 2019;15(1):235-241. doi: 10.1080/21645515.2018.1509658. Epub 2018 Sep 11. Hum Vaccin Immunother. 2019. PMID: 30118633 Free PMC article. Clinical Trial.

5

Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.

Silfverdal SA, Assudani D, Kuriyakose S, Van Der Meeren O. Silfverdal SA, et al. Hum Vaccin Immunother. 2014;10(10):2795-8. doi: 10.4161/21645515.2014.970494. Hum Vaccin Immunother. 2014. PMID: 25483640 Free PMC article.

6

Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life.

Steiner M, Ramakrishnan G, Gartner B, Van Der Meeren O, Jacquet JM, Schuster V. Steiner M, et al. BMC Infect Dis. 2010 Jan 15;10:9. doi: 10.1186/1471-2334-10-9. BMC Infect Dis. 2010. PMID: 20078876 Free PMC article.

7

Immune memory to hepatitis B persists in children aged 7-8 years, who were vaccinated in infancy with 4 doses of hexavalent DTPa-HBV-IPV/Hib (Infanrix™ hexa) vaccine.

Van Der Meeren O, Bleckmann G, Crasta PD. Van Der Meeren O, et al. Hum Vaccin Immunother. 2014;10(6):1682-7. doi: 10.4161/hv.28480. Epub 2014 Mar 17. Hum Vaccin Immunother. 2014. PMID: 24637296 Free PMC article.

8

Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib.

Zinke M, Disselhoff J; DTP a-HBV-IPV-110 and -111 study groups; Gartner B, Jacquet JM. Zinke M, et al. Hum Vaccin. 2010 Feb;6(2):189-93. doi: 10.4161/hv.6.2.10117. Hum Vaccin. 2010. PMID: 20009522 Clinical Trial.

9

Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study.

Zanetti AR, Romanò L, Giambi C, Pavan A, Carnelli V, Baitelli G, Malchiodi G, Valerio E, Barale A, Marchisio MA, Montù D, Tozzi AE, D'Ancona F; study group. Zanetti AR, et al. Lancet Infect Dis. 2010 Nov;10(11):755-61. doi: 10.1016/S1473-3099(10)70195-X. Epub 2010 Sep 29. Lancet Infect Dis. 2010. PMID: 20884297 Clinical Trial.

10

Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses.

Heininger U; DTP-HBV-IPV-059 Study Group; DTP-HBV-IPV-096 Study Group; Sänger R, Jacquet JM, Schuerman L. Heininger U, et al. Vaccine. 2007 Jan 22;25(6):1055-63. doi: 10.1016/j.vaccine.2006.09.060. Epub 2006 Oct 2. Vaccine. 2007. PMID: 17049692 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

171 results

Results by year